Tony Jackson

Our writers adhere to IBT's Editorial Guidelines.
More From Tony Jackson

Top 5 Personal Injury Lawyers in Melbourne 2026: Expert Guide to Victoria's Best Compensation Attorneys

MELBOURNE, Australia — As road accidents, workplace injuries and public liability claims continue to rise across Victoria, injured Victorians are turning to specialist personal injury lawyers to secure fair compensation under the state's complex no-fault and common law systems. In 2026, a handful of firms and practitioners stand out for their track records, peer recognition and client-focused "no win, no fee" models.
Apr 12, 2026

Buy or Sell Organon Stock in 2026? Takeover Buzz Lifts Shares 28% as Analysts Stay Cautious

JERSEY CITY, N.J. — Shares of Organon & Co. surged more than 27% on April 10, 2026, closing at $8.83 after reports emerged that India's Sun Pharmaceutical Industries is nearing a potential $12 billion all-cash takeover offer for the women's health and biosimilars specialist, injecting fresh drama into a stock that has struggled with flat growth and heavy debt.
Apr 12, 2026

NVIDIA Stock 2026: Buy or Sell NVDA as AI Demand and Blackwell Ramp Fuel Strong Buy Consensus

NEW YORK — NVIDIA Corp. (NASDAQ: NVDA) shares closed at approximately $188.63 on April 10, 2026, with Wall Street analysts maintaining a strong consensus "Buy" or "Strong Buy" rating as the company rides explosive demand for its AI GPUs, particularly the Blackwell platform, despite concerns over lofty valuations and potential slowdowns in hyperscaler capital spending.
Apr 12, 2026

Fluence Energy Stock Jumps 7% as Battery Storage Leader Rides AI Data Center Boom

NEW YORK — Fluence Energy Inc. shares climbed more than 7% in morning trading Friday, reaching $14.56 as investors bet on the battery storage company's strong positioning in the surging U.S. energy storage market fueled by artificial intelligence data centers, grid modernization and supportive domestic manufacturing policies.
Apr 11, 2026

ImmunityBio Stock Climbs 7% as Record $44M Q1 Revenue from ANKTIVA Fuels Biotech Rally

Shares of ImmunityBio Inc. rose sharply midday Thursday as the commercial-stage immunotherapy company reported record preliminary first-quarter 2026 net product revenue of approximately $44.2 million from its flagship bladder cancer therapy ANKTIVA, marking a 168% increase from the same period last year and underscoring accelerating commercial traction despite a recent FDA warning on promotional materials.
Apr 10, 2026

Pages

  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • NEXT